Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

Fig. 1

Sarilumab decreases markers of joint damage and inflammation in MOBILITY parts A and B (a and b, C1M; c and d, C2M; e and f, C3M; g, CRPM; and h, MMP-3). *p < 0.05 vs placebo. **p < 0.01 vs placebo. ***p < 0.0001 vs placebo. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CRPM C-reactive protein MMP-derived fragment, MMP-3 matrix metalloproteinase 3, MTX methotrexate, NS not significant, (Q1,Q3) quartile 1 to quartile 3 interval, q2w every 2 weeks

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us